# A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC

> **NCT07692048** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Sichuan University** · enrollment: 21 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** SYS6010

## Key facts

- **NCT ID:** NCT07692048
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07692048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07692048, "A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07692048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*